Gyre Therapeutics (GYRE) Competitors $7.78 +0.32 (+4.22%) As of 09:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE vs. KYMR, VKTX, MOR, CRNX, ALVO, MLTX, CPRX, IMVT, HCM, and OGNShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), MoonLake Immunotherapeutics (MLTX), Catalyst Pharmaceuticals (CPRX), Immunovant (IMVT), HUTCHMED (HCM), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Its Competitors Kymera Therapeutics Viking Therapeutics MorphoSys Crinetics Pharmaceuticals Alvotech MoonLake Immunotherapeutics Catalyst Pharmaceuticals Immunovant HUTCHMED Organon & Co. Gyre Therapeutics (NASDAQ:GYRE) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation. Does the media refer more to GYRE or KYMR? In the previous week, Kymera Therapeutics had 29 more articles in the media than Gyre Therapeutics. MarketBeat recorded 31 mentions for Kymera Therapeutics and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.63 beat Kymera Therapeutics' score of 0.46 indicating that Gyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in GYRE or KYMR? 24.0% of Gyre Therapeutics shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is GYRE or KYMR more profitable? Gyre Therapeutics has a net margin of 7.20% compared to Kymera Therapeutics' net margin of -409.07%. Gyre Therapeutics' return on equity of 9.73% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics7.20% 9.73% 7.66% Kymera Therapeutics -409.07%-30.11%-25.65% Do analysts rate GYRE or KYMR? Kymera Therapeutics has a consensus price target of $59.11, suggesting a potential upside of 32.12%. Given Kymera Therapeutics' higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better earnings and valuation, GYRE or KYMR? Gyre Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.76M6.89$12.09M$0.02388.75Kymera Therapeutics$47.07M61.90-$223.86M-$3.10-14.43 Which has more risk & volatility, GYRE or KYMR? Gyre Therapeutics has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. SummaryGyre Therapeutics beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$726.17M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio388.9421.3126.1819.90Price / Sales6.89278.47413.85113.66Price / Cash37.7741.4736.1356.90Price / Book7.407.518.045.38Net Income$12.09M-$55.05M$3.15B$248.50M7 Day Performance5.35%2.07%1.37%2.04%1 Month Performance-5.41%4.84%3.55%4.84%1 Year Performance-33.66%5.37%34.85%20.23% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.207 of 5 stars$7.78+4.2%N/A-35.4%$726.17M$105.76M388.9440KYMRKymera Therapeutics3.1374 of 5 stars$46.29+0.9%$59.82+29.2%+47.4%$2.99B$58.89M-14.93170Analyst ForecastInsider TradeAnalyst RevisionVKTXViking Therapeutics4.1795 of 5 stars$24.86-4.4%$87.15+250.6%-46.2%$2.92BN/A-21.6220MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.6024 of 5 stars$29.91-0.8%$74.56+149.3%-35.4%$2.82B$1.04M-7.83210ALVOAlvotech3.3696 of 5 stars$9.13-2.4%$18.00+97.2%-27.0%$2.82B$491.98M24.681,032MLTXMoonLake Immunotherapeutics2.2967 of 5 stars$44.87+3.1%$78.71+75.4%+19.2%$2.78BN/A-19.512CPRXCatalyst Pharmaceuticals4.9287 of 5 stars$22.12-1.6%$32.83+48.4%+35.8%$2.74B$491.73M14.0980Positive NewsIMVTImmunovant2.2361 of 5 stars$15.47-2.1%$38.33+147.8%-36.6%$2.70BN/A-5.65120HCMHUTCHMED1.787 of 5 stars$15.21+2.5%$19.00+24.9%-8.9%$2.59B$630.20M0.001,811Positive NewsOGNOrganon & Co.4.8243 of 5 stars$9.82+0.7%$18.00+83.3%-49.5%$2.53B$6.40B3.414,000Trending News Related Companies and Tools Related Companies Kymera Therapeutics Competitors Viking Therapeutics Competitors MorphoSys Competitors Crinetics Pharmaceuticals Competitors Alvotech Competitors MoonLake Immunotherapeutics Competitors Catalyst Pharmaceuticals Competitors Immunovant Competitors HUTCHMED Competitors Organon & Co. Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GYRE) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
